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Article
Introduction
The diagnostic criteria for ADHD require that patients expe-
rience not only symptoms of inattention and/or hyperactiv-
ity–impulsivity but also interference with or reduced quality 
of functioning in social, academic, or occupational domains 
(American Psychiatric Association, 2000, 2013). Based on 
this definition, ADHD is therefore expected to have a nega-
tive impact across multiple domains of patients’ health-
related quality of life (HRQoL; Coghill & Hodgkins, 2016; 
Danckaerts et al., 2010). Following guidance from the 
European Medicines Agency that clinical efficacy trials of 
ADHD medications should assess both ADHD symptoms 
and functional impairments (European Medicines Agency, 
2010), recent studies have included functional impairment 
and/or HRQoL measures as well as symptom-based mea-
sures (Coghill, 2011). ADHD symptoms, functional impair-
ments, and HRQoL are hypothesized to be related, but 
distinct constructs, raising the question of the extent of con-
gruence or divergence between the instruments used to assess 
these outcomes in clinical trials. It is therefore important that 
functional impairment and HRQoL instruments are able to 
tap into domains of impairment that are relevant to ADHD, 
but that they are not simply surrogate measures of ADHD 
symptoms (Coghill, Danckaerts, Sonuga-Barke, Sergeant, & 
ADHD European Guidelines Group, 2009).
Among the instruments commonly used to assess 
HRQoL and functional impairments in clinical trials of 
ADHD medications are the Child Health and Illness 
Profile–Child Edition: Parent Report Form (CHIP-CE:PRF) 
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Abstract
Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional 
impairments, and health-related quality of life in children and adolescents with ADHD. Method: Pearson correlation 
coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and 
active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-
release (atomoxetine reference). Results: Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally 
correlated moderately with changes in Child Health and Illness Profile−Child Edition: Parent Report Form (CHIP-CE:PRF) 
Achievement and Risk Avoidance (r ≈ .4), but weakly with Resilience, Satisfaction, and Comfort (r ≈ .2); and moderately 
with Weiss Functional Impairment Rating Scale–Parent (WFIRS-P) total score (r ≈ .5). CHIP-CE:PRF Achievement and Risk 
Avoidance correlated moderately to strongly with WFIRS-P total score (r ≈ .6). Conclusion: The ADHD-RS-IV, CHIP-
CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD. (J. of 
Att. Dis. XXXX; XX(X) XX-XX)
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and the Weiss Functional Impairment Rating Scale–Parent 
(WFIRS-P), respectively (Banaschewski et al., 2014; 
Banaschewski et al., 2013; Coghill, 2010; Coghill et al., 
2013; Danckaerts et al., 2010; Escobar, Schacht, Wehmeier, 
& Wagner, 2010; Hervas et al., 2014; Nagy et al., 2016). 
While both are parent-rated instruments intended for use in 
children, the CHIP-CE:PRF is a generic HRQoL instrument 
(not specific for any disease or disorder), whereas the 
WFIRS-P was designed around functional impairments that 
are most relevant to patients with ADHD (but not necessar-
ily unique to ADHD).
The CHIP-CE:PRF has been psychometrically validated 
in population samples (Estrada et al., 2010; Riley et al., 
2004) and in children and adolescents with ADHD (Riley, 
Coghill, et al., 2006; Schacht, Escobar, Wagner, & 
Wehmeier, 2011). Scores on the 76-item questionnaire are 
normalized to T-scores using data from a U.S. reference 
population for each of the five CHIP-CE:PRF domains 
(Achievement, Risk Avoidance, Resilience, Satisfaction, 
and Comfort) and 12 nested subdomains (Estrada et al., 
2010; Riley et al., 2004). The Achievement domain (10 
items) assesses children’s role performance at school and 
with peers, and comprises the subdomains of Academic 
Performance and Peer Relations. The Risk Avoidance 
domain (14 items) assesses children’s ability to refrain from 
behaviors that may lead to illness or injury or that may 
interfere with social development and comprises the subdo-
mains of Individual Risk Avoidance and Threats to 
Achievement. The Resilience domain (19 items) assesses 
children’s family support, coping abilities, and physical 
activity levels, and comprises the subdomains of Family 
Involvement, Social Problem-Solving, and Physical 
Activity. The Satisfaction domain (11 items) assesses chil-
dren’s well-being and self-esteem, and comprises the sub-
domains of Satisfaction with Health and Satisfaction with 
Self. The Comfort domain assesses children’s positive and 
negative physical and emotional symptoms and feelings 
and limitations in their day-to-day activities, and comprises 
the subdomains of Physical Comfort, Emotional Comfort, 
and Restricted Activity (Riley et al., 2004). The WFIRS-P 
has also been psychometrically validated in children and 
adolescents with ADHD (Dose, Hautmann, & Döpfner, 
2016; Gajria et al., 2015; Tarakcioglu, Memik, Olgun, 
Aydemir, & Weiss, 2015). Scores from 0 to 3 on the 50-item 
questionnaire are reported as the mean score in total and in 
each of the six WFIRS-P domains: Family, Learning and 
School (with subdomains of Learning and Behavior), Life 
Skills, Child’s Self-Concept, Social Activities, and Risky 
Activities. The complete WFIRS-P questionnaire is avail-
able on the Canadian ADHD Resource Alliance (CADDRA; 
2014) website.
Here, we use data from two recent Phase 3 clinical trials 
of stimulant and nonstimulant ADHD medications to inves-
tigate the relationships between symptom-based, functional 
impairment, and HRQoL outcomes in children and adoles-
cents with ADHD. Both the CHIP-CE:PRF and WFIRS-P 
were secondary efficacy outcome measures in a placebo-
controlled study of the stimulant prodrug lisdexamfetamine 
(LDX) that included an osmotic-release oral system meth-
ylphenidate (OROS-MPH) reference arm (study SPD489-
325; Banaschewski et al., 2013; Coghill et al., 2013); and 
the WFIRS-P was a secondary efficacy outcome measure in 
a placebo-controlled study of the selective α
2A
 adrenergic 
receptor agonist guanfacine extended-release (GXR) that 
included an atomoxetine (ATX) reference arm (study 
SPD503-316; Hervas et al., 2014). In concordance with the 
results of previous studies and meta-analyses (Cheng, Chen, 
Ko, & Ng, 2007; Punja et al., 2016; Storebo et al., 2015; 
Stuhec, Munda, Svab, & Locatelli, 2015), all four of the 
medications studied in these two clinical trials were signifi-
cantly more effective than placebo in relieving ADHD 
symptoms, as assessed using the investigator-rated ADHD 
Rating Scale IV (ADHD-RS-IV; Coghill et al., 2013; 
Hervas et al., 2014). Secondary efficacy outcomes in 
SPD489-325 showed that LDX and OROS-MPH were sig-
nificantly more effective than placebo in improving CHIP-
CE:PRF T-scores in the domains of Achievement, Risk 
Avoidance, Resilience, and Satisfaction, and in improving 
WFIRS-P total scores (and WFIRS-P scores in the domains 
of Family, Learning and School, Social Activities, and 
Risky Activities for both medications, and in Life Skills and 
Child’s Self-Concept for OROS-MPH only; Banaschewski 
et al., 2013). Secondary efficacy outcomes in SPD503-316 
showed that GXR and ATX were more effective than pla-
cebo in improving WFIRS-P total scores (and scores in the 
domains of Learning and School for both medications, and 
in Family and Social Activities for GXR only; Hervas et al., 
2014). Safety outcomes from both studies were consistent 
with those of previous studies and indicated that the medi-
cations were generally well tolerated (Coghill et al., 2013; 
Hervas et al., 2014).
In the present post hoc analyses, we use correlational 
analyses to investigate the associations between changes 
from baseline to endpoint in ADHD-RS-IV, CHIP-CE:PRF, 
and WFIRS-P scores in SPD489-325, and ADHD-RS-IV 
and WFIRS-P scores in SPD489-316. We hypothesized that 
very strong correlations (Evans, 1996) with ADHD-RS-IV 
would be observed if the CHIP-CE:PRF and WFIRS-P 
instruments effectively acted as additional measures of 
ADHD symptoms, and that very weak or no correlations 
would be observed if the CHIP-CE:PRF and WFIRS-P 
instruments assessed impairments and HRQoL deficits that 
are not connected with ADHD symptoms. In contrast, mod-
erate correlations between these outcome measures would 
be observed if the instruments assessed symptoms, func-
tional impairments, and HRQoL as separable but intercon-
nected aspects of the treatment response in patients with 
ADHD.
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Method
Studies
The present article describes post hoc analyses of results 
from two separate randomized, double-blind, placebo-con-
trolled efficacy and safety trials, one of LDX with an 
OROS-MPH reference arm and one of GXR with an ATX 
reference arm. Summaries of the published prespecified 
efficacy analyses are provided for context. The reference 
arms were included in the studies and prespecified analyses 
as active controls (established treatments known to be supe-
rior to placebo), rather than as direct comparators. The pur-
pose of an active control is to aid interpretation of results if 
the primary endpoint is not met for the investigational prod-
uct. The studies were neither designed nor powered for 
comparisons between active treatments.
Study SPD489-325 (ClinicalTrials.gov NCT00763971) 
was a randomized, double-blind, placebo-controlled, Phase 
3 trial of the efficacy and safety of LDX in children and 
adolescents with ADHD in Europe (48 sites in 10 coun-
tries). OROS-MPH was included as a reference treatment. 
Details of the study design, results, and previous post hoc 
analyses are published (Banaschewski et al., 2013; Coghill 
et al., 2013; Coghill et al., 2014; Soutullo et al., 2013).
Study SPD503-316 (ClinicalTrials.gov NCT01244490) 
was a randomized, double-blind, placebo-controlled, Phase 
3 trial of the efficacy and safety of GXR in children and 
adolescents with ADHD in Europe (45 sites in 11 coun-
tries), the United States (11 sites), and Canada (two sites). 
ATX was included as a reference treatment. Details of the 
study design, results, and previous post hoc analyses are 
published (Hervas et al., 2014; Huss et al., 2016).
Study Populations and Designs
Both studies enrolled male and female children (aged 6-12 
years) and adolescents (aged 13-17 years) with a Diagnostic 
and Statistical Manual of Mental Disorders (4th ed., text 
rev.; DSM-IV-TR; American Psychiatric Association, 2000) 
diagnosis of ADHD and an ADHD-RS-IV total score of at 
least 28 (LDX study SPD489-325) or at least 32 (GXR 
study SPD503-316). Children and adolescents were 
excluded from the study if they had a comorbid psychiatric 
diagnosis (except oppositional defiant disorder) or if their 
current ADHD medication provided effective control of 
symptoms with acceptable tolerability (Coghill et al., 2013; 
Hervas et al., 2014). In the LDX study, children and adoles-
cents were excluded if there had been a failed response to 
previous OROS-MPH treatment (Coghill et al., 2013).
Following screening and washout, enrolled participants 
were randomized (1:1:1) to receive LDX, placebo, or the 
OROS-MPH reference treatment for a double-blind treat-
ment period of 7 weeks in SPD489-325; or to receive GXR, 
placebo, or the ATX reference treatment for a double-blind 
treatment period of 10 weeks for children or 13 weeks for 
adolescents in SPD503-316. In both studies, recruitment 
management ensured that about 25% of those enrolled were 
adolescents, and randomization was stratified by country 
and age group (children or adolescents; Coghill et al., 2013; 
Hervas et al., 2014). For regulatory reasons, at least 70% of 
enrolled participants in the GXR study were to be recruited 
in Europe (Hervas et al., 2014).
Study Drug Administration
In SPD489-325, doses were optimized to LDX 30, 50, or 70 
mg/day or OROS-MPH 18, 36, or 54 mg/day from Week 0 
to Week 4, and these doses were maintained for the remain-
der of the 7-week double-blind treatment period. Dose 
alterations (weekly stepwise increases or a single decrease) 
were permitted during dose optimization but not dose main-
tenance (Coghill et al., 2013). OROS-MPH 54 mg/day is 
the maximum dose approved in Europe.
In SPD503-316, doses were optimized to GXR 1 to 7 
mg/day (up to a maximum of 4, 5, 6, or 7 mg/day depending 
on age and body weight as previously described), or ATX 
0.5 or 1.2 mg/kg/day (for patients weighing <70 kg; maxi-
mum 1.4 mg/kg/day) or 40, 80, or 100 mg/day (for patients 
weighing ≥70 kg) from Week 0 to Week 4 (for children) or 
to Week 7 (for adolescents), and these doses were main-
tained for the remainder of the 10-week (for children) or 
13-week (for adolescents) double-blind treatment period 
(Hervas et al., 2014). Dose alterations (weekly stepwise 
increases or a single decrease) were permitted during dose 
optimization but not dose maintenance (Hervas et al., 2014). 
ATX was titrated in accordance with the European market-
ing authorization.
Study Assessments
The primary efficacy outcome in both studies was the 
change in ADHD-RS-IV total score from baseline to end-
point (defined as the last on-treatment assessment with 
valid data, excluding baseline; Coghill et al., 2013; Hervas 
et al., 2014). Both studies included the WFIRS-P, and the 
LDX study also included the CHIP-CE:PRF among other 
secondary efficacy outcome measures (Banaschewski et al., 
2013; Coghill et al., 2013; Coghill et al., 2014; Hervas 
et al., 2014; Huss et al., 2016; Soutullo et al., 2013). In the 
LDX study, the CHIP-CE:PRF Achievement domain was 
prespecified as the primary HRQoL outcome (Banaschewski 
et al., 2013); in the GXR study, the WFIRS-P Learning and 
School domain and Family domain were prespecified as 
key secondary efficacy outcomes. Safety was assessed as 
previously described (Coghill et al., 2013; Hervas et al., 
2014).
Investigators completed the ADHD-RS-IV at baseline 
and at each weekly study visit in the double-blind period of 
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both studies, based on all available information at each 
assessment. Participants’ parents (or legally authorized rep-
resentatives) completed the CHIP-CE:PRF and WFIRS-P at 
baseline, Week 4 (for participants enrolled after a protocol 
amendment), Week 7, and/or at early termination in the 
LDX study. Participants’ parents (or legally authorized rep-
resentative) completed the WFIRS-P at baseline, Week 4, 
Week 7, Week 10, Week 13 (for adolescents only), and/or at 
early termination in the GXR study (Banaschewski et al., 
2013; Hervas et al., 2014).
Prespecified Statistical Analyses
In both studies, efficacy analyses were based on the full 
analysis set, defined as participants who were randomized 
and took at least one dose of study drug. The full analysis 
set in the LDX study excluded 15 patients from one site 
where there were violations of good clinical practice; and 
the full analysis set in the GXR study excluded one patient 
who was randomized to GXR but was lost to follow-up 
before receiving treatment (Coghill et al., 2013; Hervas 
et al., 2014). The “last observation carried forward” 
approach to missing data was used in both studies for all 
outcome measures (Banaschewski et al., 2013; Coghill 
et al., 2013; Hervas et al., 2014). The methods for determin-
ing sample sizes have been previously described (Coghill 
et al., 2013; Hervas et al., 2014). Prespecified analyses used 
ANCOVA models of the difference in least squares (LS) 
mean changes from baseline for each study treatment group 
compared with placebo (α = .05) in ADHD-RS-IV and 
WFIRS-P scores in both studies and also for CHIP-CE:PRF 
T-scores in the LDX study (Banaschewski et al., 2013; 
Coghill et al., 2013; Hervas et al., 2014). Effect sizes were 
calculated as the difference in LS means between each 
active drug and placebo, divided by the root mean square 
error from the ANCOVA models. Effect sizes calculated 
using this method are similar to Cohen’s d and are conven-
tionally interpreted as large (>0.8), medium (0.5-<0.8), or 
small (0.2-<0.5; Cohen, 1992).
Both studies used a prespecified hierarchical testing 
algorithm to control Type I error. The primary efficacy out-
come was tested first, followed in rank order by each key 
secondary outcome. Statistical significance was only 
declared for an outcome if the p value was below .05 and 
the previous outcome in the algorithm was also declared 
significant. This means that p values below .05 reported in 
this article are statistically significant only for the primary 
efficacy outcome and the key HRQoL outcome in the LDX 
group of SPD489-325 (change from baseline to endpoint in 
ADHD-RS-IV total score and CHIP-CE:PRF Achievement 
domain T-score, respectively) and for the primary efficacy 
outcome and key secondary efficacy outcomes in the GXR 
group of SPD503-316 (change from baseline to endpoint in 
ADHD-RS-IV total score and WFIRS-P Learning and 
School domain and Family domain scores, respectively). 
Analyses of all other outcomes were not included in the 
hierarchical testing algorithm, so they are not controlled for 
multiplicity and their associated p values are descriptive 
and noninferential.
Post Hoc Statistical Analyses
Pearson correlation coefficients (r) were calculated post 
hoc for the change in scores from baseline to endpoint in 
the following: ADHD-RS-IV total score versus T-scores 
in each of the five CHIP-CE:PRF domains (in the LDX 
study only), ADHD-RS-IV total score versus WFIRS-P 
total score and scores in each of the six WFIRS-P domains 
(in both studies), and T-scores in each of the five CHIP-
CE:PRF domains versus WFIRS-P total score and in 
scores in each of the six WFIRS-P domains (in the LDX 
study only). Data for each treatment group were analyzed 
separately (results for the placebo group are not reported). 
Values of r were not compared statistically with one 
another across instruments, domains, or treatment groups. 
These exploratory analyses were not corrected for multi-
ple comparisons, and p values are descriptive and nonin-
ferential. Pearson’s r is a measure of the strength of a 
positive or negative linear relationship between paired 
data, and may be interpreted as indicating very weak (r < 
.2), weak (.2-<.4), moderate (.4-<.6), strong (.6-<.8), or 
very strong (.8-<1.0) correlations (Evans, 1996).
Results
Participant Characteristics and Disposition
In the LDX study (Banaschewski et al., 2013; Coghill et al., 
2013), 336 participants were randomized and 317 were 
included in the full analysis set, of whom 77/104, 42/106, 
and 72/107 in the LDX, placebo, and OROS-MPH groups, 
respectively, completed the study. The principal reason for 
study discontinuation was lack of efficacy. Baseline demo-
graphics and disease characteristics were similar across 
treatment groups. The mean age of participants in the full 
analysis set was 10.9 years (SD = 2.70), and 72.2% were 
children aged 6 to 12 years.
In the GXR study (Hervas et al., 2014), 338 participants 
were randomized and 337 were included in the full analysis 
set, of whom 91/114, 89/112, and 92/111 in the GXR, pla-
cebo, and ATX groups, respectively, completed the double-
blind period of the study. Of the 338 randomized participants, 
77.5% were enrolled in Europe. The principal reason for 
study discontinuation was lack of efficacy. Baseline demo-
graphics and disease characteristics were similar across 
treatment groups. The mean age of participants in the full 
analysis set was 10.8 years (SD = 2.77), and 71.8% were 
children aged 6 to 12 years.
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ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P 
Outcomes: Change From Baseline to Endpoint
In the LDX study, mean improvements in ADHD-RS-IV 
total score from baseline to endpoint were significantly 
greater for LDX and the OROS-MPH reference treatment 
than for placebo, with effect sizes of 1.80 and 1.26, respec-
tively (Table 1; Coghill et al., 2013). Improvements in 
CHIP-CE:PRF T-scores were significantly greater for LDX 
and OROS-MPH than for placebo in four of the five 
domains, with large effect sizes in Achievement and Risk 
Avoidance, small effect sizes in Resilience and Satisfaction, 
and no significant effect in Comfort (Table 1; Banaschewski 
et al., 2013). Improvement in WFIRS-P total score was sig-
nificantly greater for LDX and OROS-MPH than for pla-
cebo, with a large effect size for LDX and a medium effect 
size for OROS-MPH. In four of the six WFIRS-P domains, 
improvements were significantly greater for LDX and 
OROS-MPH than for placebo: Learning and School (large 
effect sizes for both treatments), Family and Social 
Activities (medium effect sizes for both treatments), and 
Risky Activities (medium effect size for LDX, small effect 
size for OROS-MPH; Table 1). OROS-MPH also had a sig-
nificantly greater effect than placebo in Life Skills and 
Child’s Self-Concept, with small effect sizes (Banaschewski 
et al., 2013).
In the GXR study, mean improvements in ADHD-RS-IV 
total score from baseline to endpoint were significantly 
greater for GXR and the ATX reference treatment than for 
placebo, with effect sizes of 0.76 and 0.32, respectively 
(Table 2; Hervas et al., 2014). Improvements in WFIRS-P 
total score were significantly greater for GXR and ATX 
than for placebo, with small effect sizes. In the six WFIRS-P 
domains, improvements were significantly greater for GXR 
and ATX than for placebo in Learning and School, with 
small effect sizes, and for GXR only in Family and Social 
Activities, with small effect sizes (Table 2; Hervas et al., 
2014).
Correlation of Change in ADHD-RS-IV Score 
With Change in CHIP-CE:PRF T-Scores
In the LDX and OROS-MPH groups, changes in ADHD-
RS-IV total score from baseline to endpoint in SPD489-
325 correlated most moderately with changes in 
CHIP-CE:PRF domain T-scores (Figure 1). The strongest 
nominally significant correlations for both active treat-
ments were with changes in the Risk Avoidance domain 
Table 1. Summary of Efficacy Outcomes in the LDX Study (SPD489-325).
Outcome
LDXa OROS-MPHa
Placebo-adjusted LS-mean 
change (95% CI)b
Effect size versus 
placeboc
Placebo-adjusted LS-
mean change (95% CI)b
Effect size 
versus placeboc
ADHD-RS-IV
 Total score −18.6 [−21.5, −15.7] 1.80*** −13.0 [−15.9, −10.2] 1.26***
CHIP-CE:PRF
 Achievement 10.5 [7.9, 13.0] 1.28*** 7.5 [4.9, 10.0] 0.91***
 Risk avoidance 9.9 [7.1, 12.7] 1.08*** 8.7 [5.9, 11.5] 0.95***
 Resilience 3.8 [1.1, 6.6] 0.42** 3.6 [0.8, 6.4] 0.40*
 Satisfaction 3.5 [0.6, 6.5] 0.37* 3.4 [0.4, 6.3] 0.35*
 Comfort 0.0 [−2.6, 2.6] 0.00 1.5 [−1.1, 4.2] 0.18
WFIRS-P
 Total score −0.29 [−0.39, −0.19] 0.92*** −0.24 [−0.34, −0.15] 0.77***
 Family −0.37 [−0.53, −0.22] 0.73*** −0.33 [−0.49, −0.18] 0.65***
 Learning and school −0.54 [−0.67, −0.41] 1.25*** −0.39 [−0.53, −0.26] 0.91***
 Life skills −0.09 [−0.21, 0.02] 0.24 −0.13 [−0.25, −0.02] 0.35*
 Child’s self-concept −0.17 [−0.36, 0.03] 0.26 −0.23 [−0.42, −0.04] 0.36*
 Social activities −0.26 [−0.39, −0.14] 0.64*** −0.25 [−0.37, −0.12] 0.60***
 Risky activities −0.17 [−0.26, −0.09] 0.64*** −0.11 [−0.20, −0.03] 0.41*
Note. LDX = lisdexamfetamine; OROS-MPH = osmotic-release oral system methylphenidate; LS = least squares; CI = confidence interval;  
ADHD-RS-IV = ADHD Rating Scale IV; CHIP-CE:PRF = Child Health and Illness Profile−Child Edition: Parent Report Form; WFIRS-P = Weiss  
Functional Impairment Rating Scale–Parent.
aData are from the full analysis set (LDX, n = 104; placebo, n = 106; OROS-MPH, n = 107).
bChanges are from baseline to endpoint (defined as the last on-treatment assessment with valid data, excluding baseline). Improvement is indicated by 
increasing CHIP-CE:PRF T-scores and decreasing ADHD-RS-IV and WFIRS-P scores.
cAll p values are nominal except for ADHD-RS-IV total score and CHIP-CE:PRF achievement in the LDX group only. The study was not designed or 
powered for comparison of LDX with OROS-MPH.
*p < .05. **p < .01. ***p < .001. (versus placebo; ANCOVA model with treatment, country, and age group as fixed effects and baseline score as covariate)
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(LDX, r = −.44; OROS-MPH, r = −.42) and the 
Achievement domain (LDX, r = −.36; OROS-MPH r = 
−.48). For changes in the remaining three domains, corre-
lations were weak but significant for both active 
Table 2. Summary of Efficacy Outcomes in the GXR Study (SPD503-316).
Outcome
GXRa ATXa
Placebo-adjusted
LS-mean change
(95% CI)b
Effect size 
versus placeboc
Placebo-adjusted
LS-mean change
(95% CI)b
Effect size 
versus placeboc
ADHD-RS-IV
 Total score −8.9 [−11.9, −5.8] 0.76*** −3.8 [−6.8, −0.7] 0.32*
WFIRS-P
 Total score −0.17 [−0.27, −0.06] 0.44*** −0.10 [−0.21, −0.00] 0.28*
  Family −0.21 [−0.36, −0.06] 0.38** −0.09 [−0.24, 0.06] 0.16
  Learning and school −0.22 [−0.36, −0.08] 0.42** −0.16 [−0.30, −0.02] 0.32*
  Life skills −0.09 [−0.20, 0.02] 0.23 −0.07 [−0.18, 0.05] 0.16
  Child’s self-concept −0.05 [−0.19, 0.09] 0.09 −0.08 [−0.22, 0.07] 0.15
  Social activities −0.23 [−0.37, −0.09] 0.45** −0.11 [−0.25, 0.03] 0.21
  Risky activities −0.06 [−0.13, 0.02] 0.21 −0.04 [−0.12, 0.04] 0.14
Note. GXR = guanfacine extended-release; ATX = atomoxetine; LS = least squares; CI = confidence interval; ADHD-RS-IV = ADHD Rating Scale IV; 
WFIRS-P = Weiss Functional Impairment Rating Scale–Parent.
aData are from the full analysis set (GXR, n = 114; placebo, n = 111; ATX, n = 112).
bChanges are from baseline to endpoint (defined as the last on-treatment assessment with valid data, excluding baseline). Improvement is indicated by 
decreasing ADHD-RS-IV and WFIRS-P scores.
cAll p values are nominal except for ADHD-RS-IV total score, WFIRS-P Learning and School, and WFIRS-P Family in the GXR group only. The study 
was not designed or powered for comparison of GXR with ATX.
*p < .05. **p < .01. ***p < .001. (versus placebo; ANCOVA model with treatment, country, and age group as fixed effects and baseline score as covariate)
Figure 1. Pearson correlation coefficients for change in ADHD-RS-IV total score versus change in CHIP-CE:PRF T-score in the LDX 
study (SPD489-325).
Note. Intensity of cell shading indicates the value of Pearson’s r as shown in the key. Categorical interpretation of r values as a strength of correlation 
is for guidance only. Numbers of observations (n) used for analyses were in the ranges indicated and varied across domains depending on data validity. 
ADHD-RS-IV = ADHD Rating Scale IV; CHIP-CE:PRF = Child Health and Illness Profile−Child Edition: Parent Report Form; LDX = lisdexamfetamine; 
OROS-MPH = osmotic-release oral system methylphenidate.
*p < .05. **p < .01. ***p < .001. (nominal)
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treatments in Satisfaction and Comfort and for LDX in 
Resilience, and were very weak and not significant for 
OROS-MPH in Resilience (Figure 1).
Correlation of Change in ADHD-RS-IV Score 
With Change in WFIRS-P Scores
Changes in ADHD-RS-IV total score from baseline to end-
point correlated moderately and nominally significantly 
with changes in WFIRS-P total score in the LDX and 
OROS-MPH groups in SPD489-325 and the GXR group in 
SPD503-316, with r values of .51, .49, and .56, respectively 
(Figure 2). The correlation of change in ADHD-RS-IV with 
change in WFIRS-P total score was weak but nominally sig-
nificant in the ATX group (r = .38). In the WFIRS-P 
domains, correlations of change in all six domains with 
change in ADHD-RS-IV total score were nominally signifi-
cant, and were strongest for the Family domain in the LDX 
and OROS-MPH groups of SDP489-325 and the GXR 
group of SPD503-316 (r > .5). Moderate correlations with 
change in ADHD-RS-IV total score were also observed for 
changes in Learning and School and Risky Activities (LDX 
group and GXR group only) and Child’s Self-Concept and 
Social Activities (GXR group only) domain scores. All 
other correlations were weak but nominally significant 
(including all domains in the ATX group).
Correlation of CHIP-CE:PRF Outcomes With 
WFIRS-P Outcomes
Changes in CHIP-CE:PRF Achievement domain and Risk 
Avoidance domain T-scores correlated strongly and nomi-
nally significantly with changes in WFIRS-P total score in 
the active treatment groups of study SPD489-325, with r 
values of −.65 and −.62 in the LDX group and −.59 and 
−.62 in the OROS-MPH group, respectively (Figure 3). 
Nominally significant correlations with change in WFIRS-P 
total score were moderate for changes in the remaining 
CHIP-CE:PRF domains of Satisfaction (LDX, r = −.50; 
OROS-MPH, r = −.44), and weak to moderate for Resilience 
and Comfort (LDX, r = −.37 and −.42; OROS-MPH, r = 
−.24 and −.33, respectively).
In pairwise correlations of change in the five CHIP-
CE:PRF domains with change in each of the six WFIRS-P 
domains (Figure 3), change in CHIP-CE:PRF Risk 
Avoidance correlated most strongly with change in 
WFIRS-P Risky Activities (LDX, r = −.71; OROS-MPH, 
r = −.56), but also moderately and nominally significantly 
with change in Family, Learning and School, and Child’s 
Self-Concept in both groups (LDX, r = −.50, −.53, and 
−.55; OROS-MPH, r = −.50, −.46, and −.41, respectively) 
and Social Activities in the LDX group (r = −.49). Change 
in CHIP-CE:PRF Achievement correlated most strongly 
Figure 2. Pearson correlation coefficients for change in ADHD-RS-IV total score versus change in WFIRS-P total and domain scores 
in studies SPD489-325 and SPD503-316.
Note. Intensity of cell shading indicates the value of Pearson’s r as shown in the key. Categorical interpretation of r values as a strength of correlation 
is for guidance only. Numbers of observations (n) used for analyses were in the ranges indicated and varied across domains depending on data valid-
ity. ADHD-RS-IV = ADHD Rating Scale IV; WFIRS-P = Weiss Functional Impairment Rating Scale–Parent; LDX = lisdexamfetamine; OROS-MPH = 
osmotic-release oral system methylphenidate; GXR = guanfacine extended-release; ATX, atomoxetine.
*p < .05. **p < .01. ***p < .001. (nominal)
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with change in WFIRS-P Learning and School (LDX, r = 
−.54; OROS-MPH, r = −.59) and Risky Activities (LDX, 
r = −.58; OROS-MPH, r = −.40), but also moderately and 
nominally significantly with change in Family and Social 
Activities in the LDX group (r = −.50 and −.45, respec-
tively) and Child’s Self-Concept in both groups (LDX, r 
= −.40; OROS-MPH, r = −.43). Changes in CHIP-CE:PRF 
Resilience, Satisfaction, and Comfort correlated weakly 
or very weakly with changes in the WFIRS-P domains, 
except for the moderate correlations of change in CHIP-
CE:PRF Satisfaction with change in WFIRS-P Child’s 
Self-Concept in both groups (LDX, r = −.50; OROS-
MPH, r = −.44) and with WFIRS-P Family in the LDX 
group (r = −.46; Figure 3)
Discussion
These post hoc analyses investigated the associations 
between different symptom-based and non-symptom-based 
outcomes in two recent clinical trials involving four differ-
ent medications in children and adolescents with ADHD. 
The results are consistent with the hypothesis that the 
ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P instruments 
assess partially intersecting but distinct aspects of the 
response to pharmacological treatment. Changes in CHIP-
CE:PRF and WFIRS-P scores correlated significantly, but 
at most moderately, with changes in ADHD-RS-IV total 
score (r weaker than ± .6); the strongest relationships were 
with the CHIP-CE:PRF Achievement and Risk Avoidance 
Figure 3. Pearson correlation coefficients for change in WFIRS-P scores versus change in CHIP-CE:PRF T-scores in study SPD489-
325 in the LDX and OROS-MPH groups.
Note. Intensity of cell shading indicates the value of Pearson’s r as shown in the key. Categorical interpretation of r values as a strength of correlation 
is for guidance only. Numbers of observations (n) used for analyses were in the ranges indicated and varied across domains depending on data validity. 
WFIRS-P = Weiss Functional Impairment Rating Scale–Parent; CHIP-CE:PRF = Child Health and Illness Profile−Child Edition: Parent Report Form; 
LDX = lisdexamfetamine; OROS-MPH = osmotic-release oral system methylphenidate.
*p < .05. **p < .01. ***p < .001. (nominal)
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domains (r in the range −.36 to −.48) and the WFIRS-P total 
score and Family domain (r in the range .31-.56). 
Correlations of the CHIP-CE:PRF Achievement and Risk 
Avoidance domains with WFIRS-P total score were stron-
ger than those of either instrument with the ADHD-RS-IV, 
but were still generally only of moderate strength (r in the 
range −.59 to −.65 for WFIRS-P). These results suggest not 
only that control of ADHD symptoms was associated with 
improved functioning and HRQoL in children and adoles-
cents with ADHD in these studies, but also that the symp-
tom-based scale may not have captured a complete picture 
of the treatment response. From a clinical perspective, this 
conclusion indicates that a focus on monitoring improve-
ments in ADHD symptoms during treatment remains 
important, but that reliance solely on assessment of patients’ 
symptoms may fail to recognize continuing problems with 
functioning and HRQoL that require additional support.
Many interventional and observational studies in chil-
dren and adolescents with ADHD have included the CHIP-
CE:PRF as an outcome measure (Banaschewski et al., 2014; 
Banaschewski et al., 2013; Coghill & Hodgkins, 2016; 
Dell’Agnello et al., 2009; Escobar et al., 2009; Escobar 
et al., 2010; Hodgkins et al., 2017; Prasad et al., 2007; 
Preuss et al., 2006; Riley, Spiel, et al., 2006; Svanborg et al., 
2009). As a generic HRQoL instrument, the CHIP-CE:PRF 
contains some items that are likely to be adversely affected 
by ADHD (e.g., academic performance) and other items 
that are not (e.g., physical activities). In clinical studies, the 
largest placebo-adjusted effect sizes of stimulant medica-
tions and ATX in children and adolescents with ADHD are 
seen in the CHIP-CE:PRF domains with the most pro-
nounced baseline HRQoL deficits, namely, the Achievement 
and Risk Avoidance domains (Banaschewski et al., 2014; 
Banaschewski et al., 2013; Coghill & Hodgkins, 2016; 
Escobar et al., 2010; Riley, Spiel, et al., 2006). In the pres-
ent analyses, changes in these domains inversely correlated 
most strongly with changes in ADHD-RS-IV symptom 
scores in the LDX and OROS-MPH groups of study 
SPD489-325, consistent with the results of similar analyses 
of other studies (Coghill & Hodgkins, 2016; Escobar et al., 
2010; Riley, Coghill, et al., 2006). The large placebo-
adjusted effect sizes of LDX and OROS-MPH in these 
CHIP-CE:PRF domains were nearly as large as they were 
for the ADHD-RS-IV outcome (Table 1). LDX and OROS-
MPH also had small but nominally significant placebo-
adjusted effect sizes in the CHIP-CE:PRF domains of 
Resilience and Satisfaction, but not Comfort (Table 1); yet 
these three domains all correlated weakly with ADHD-
RS-IV, with weaker correlations in Resilience and 
Satisfaction than in Comfort (Figure 1). Taken together, 
these findings suggest that stimulant medications could 
have a proximal effect on HRQoL in domains where the 
impact of ADHD is both strong and direct (Achievement 
and Risk Avoidance), a more distal effect in domains where 
the impact is less strong and seems likely to occur via a less 
direct pathway (Resilience and Satisfaction), and little or no 
effect in domains that are hardly affected all by ADHD 
(Comfort).
The WFIRS-P has been less extensively used in studies in 
children and adolescents with ADHD than the CHIP-
CE:PRF (Banaschewski et al., 2014; Banaschewski et al., 
2013; Hervas et al., 2014; Hodgkins et al., 2017; Maziade 
et al., 2009; Nagy et al., 2016; Stein et al., 2015; Wilens 
et al., 2015). Unlike the CHIP-CE:PRF, the WFIRS-P was 
designed to focus on areas of impairment that are most prob-
lematic in patients with ADHD. This means that all six 
WFIRS-P domains contain items deemed to be characteristic 
of ADHD and that may represent important treatment targets 
(although these are not necessarily unique to ADHD). The 
design of the WFIRS-P is such that children and adolescents 
with ADHD may therefore have severe and clinically sig-
nificant impairments in only a small number of salient 
WFIRS-P items. Furthermore, the lack of normative data 
means that the severity of baseline impairments and the 
magnitude of treatment-associated improvements in 
WFIRS-P domain scores cannot be interpreted in the same 
way as CHIP-CE:PRF domain T-scores. The absolute value 
of a mean WFIRS-P domain score does not necessarily 
reflect its clinical impact. For example, estimates of mini-
mum difference that parents perceive as important are larger 
for the WFIRS-P Learning and School domain and Family 
domain than for the Risky Activities domain (Hodgkins 
et al., 2017). Despite these considerations, mean baseline 
WFIRS-P scores in children and adolescents with ADHD 
tend to indicate greater impairment in the Family domain 
and the Learning and School domain than in the other 
domains (Banaschewski et al., 2014; Banaschewski et al., 
2013; Hervas et al., 2014; Hodgkins et al., 2017; Nagy et al., 
2016; Stein et al., 2015; Wilens et al., 2015). In SPD489-
325, placebo-adjusted effect sizes of LDX and OROS-MPH 
were largest in these domains, and changes in the same 
domains (plus Risky Activities) correlated most strongly 
with ADHD-RS-IV changes, in agreement with the results 
of previous studies (Gajria et al., 2015; Stein et al., 2015; 
Tarakcioglu et al., 2015). In contrast, in the GXR group of 
SPD503-316, placebo-adjusted effect sizes were largest in 
the Social Activities and Learning and School domains, and 
changes in the same domains (plus Family) correlated most 
strongly with ADHD-RS-IV changes. This possible differ-
ence between GXR and stimulants in the two studies may 
have multiple potential explanations. First, participants’ dis-
ease severity and characteristics, including types of func-
tional impairment, may differ between studies of stimulants 
and nonstimulants. Second, the effects of different medica-
tions, with different modes of action and pharmacodynamic 
profiles, may vary over time and across domains of func-
tional impairment. Third, patients may experience functional 
improvement in different parent-reported questionnaire 
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items, which may vary in the proximity of their relationship 
to improvement in ADHD symptoms. Further studies would 
be needed to investigate whether particular medications are 
more or less suitable for patients with particular functional 
impairments.
In pairwise correlations of treatment-associated changes 
in study SPD489-325, each of the five CHIP-CE:PRF 
domains did not generally correspond to any particular 
WFIRS-P domain. Although CHIP-CE:PRF Risk Avoidance 
inversely correlated moderately to strongly with WFIRS-P 
Risky Activities, the CHIP-CE:PRF Achievement and Risk 
Avoidance domains inversely correlated at least moderately 
with all of the WFIRS-P domains except Life Skills. For the 
remaining three CHIP-CE:PRF domains, correlations with 
WFIRS-P domains were generally weak, except for CHIP-
CE:PRF Satisfaction with WFIRS-P Child’s Self-Concept. 
These results provide further indications that the CHIP-
CE:PRF Achievement and Risk Avoidance domains may be 
more proximally related to ADHD than the other domains. 
In contrast, a wider range of WFIRS-P domains than CHIP-
CE:PRF domains may be proximally related to ADHD, pos-
sibly because the disorder may be expressed as particular 
types of parent-rated functional impairment in each indi-
vidual child or adolescent. However, the WFIRS-P Child’s 
Self-Concept domain may be more distally related to 
ADHD than other domains.
In clinical trials, parent-rated HRQoL questionnaires 
like the CHIP-CE:PRF are used rather than self-rated ques-
tionnaires because children aged below 10 to 12 years may 
lack the conceptual grasp to evaluate their HRQoL accu-
rately. This involves judgment of the extent to which ill-
health affects their “perception of their position in life, in 
the context of culture and value systems in which they live, 
and in relation to their goals, expectations, standards, and 
concerns,” according to the World Health Organization def-
inition of quality of life (World Health Organization, 1995, 
p. 1403). If HRQoL is narrowly defined as being percepti-
ble only by individuals themselves, then the parent-rated 
CHIP-CE:PRF might be considered more as a measure of 
functional impairments than of HRQoL. Scores on self-
rated HRQoL instruments have been reported to correlate 
significantly but only weakly to moderately with scores on 
parent-rated HRQoL instruments, including comparisons of 
the self-rated CHIP-CE: Self-Report Form (CHIP-CE:SRF) 
with the CHIP-CE:PRF (Coghill & Hodgkins, 2016; Estrada 
et al., 2010). In the present study, using parent-rated instru-
ments, changes in CHIP-CE:PRF correlated more strongly, 
but far from perfectly, with WFIRS-P changes than with 
ADHD-RS-IV changes. This suggests that the CHIP-
CE:PRF and WFIRS-P do capture different conceptual 
aspects of the difficulties faced by children and adolescents 
with ADHD, even though the CHIP-CE:PRF does not nec-
essarily capture their own views. Furthermore, the imper-
fect correlation observed between the CHIP-CE:PRF and 
WFIRS-P instruments is consistent with the possibility that 
poor HRQoL in children and adolescents with ADHD may 
arise from their functional impairment as well as from their 
ADHD symptoms.
The strengths and weaknesses of the present post hoc 
analyses include those of the two published studies on 
which they were based (Banaschewski et al., 2013; Coghill 
et al., 2013; Hervas et al., 2014). One of the main limita-
tions of the present analyses is the inclusion of the CHIP-
CE:PRF in the LDX study but not the GXR study. Also, 
both included studies were short-term trials, and did not 
collect data on potential functional or HRQoL improve-
ments beyond the end of the study. Improvements in some 
domains of functional impairment or HRQoL may develop 
or become apparent over a longer period of time than the 
double-blind treatment period of these short-term Phase 3 
studies, especially if some domains are more distally related 
to ADHD symptoms than others. However, in an extension 
to the LDX study, most of the improvement in participants’ 
CHIP-CE:PRF and WFIRS-P scores occurred during the 
first 8 weeks of a 6-month open-label LDX treatment period 
(Banaschewski et al., 2014) and continued treatment was 
required to maintain CHIP-CE:PRF and WFIRS-P improve-
ments with LDX and to maintain WFIRS-P improvements 
with GXR in long-term randomized-withdrawal studies 
(Banaschewski et al., 2014; Newcorn et al., 2016). Another 
limitation is that the entry criteria of the two studies did not 
require participants to have functional impairments or 
HRQoL deficits, although evidence of functional impair-
ments is essential for the diagnosis of ADHD. In contrast, 
ADHD symptoms of at least moderate severity were 
required for entry in both studies (in addition to an ADHD 
diagnosis). As a result, the variance in ADHD-RS-IV total 
scores at baseline may have been constrained by the require-
ment for a minimum score at study entry. For this reason, 
we did not correlate baseline ADHD-RS-IV scores with 
baseline CHIP-CE:PRF or WFIRS-P scores. Another limi-
tation of the present analyses is that the ADHD-RS-IV was 
completed by investigators, but that the CHIP-CE:PRF and 
WFIRS-P were completed by parents. Different results may 
have been obtained with a parent-rated ADHD symptom 
instrument. Finally, the present analyses were confined to 
two clinical trials and did not include other studies that have 
used the CHIP-CE:PRF and WFIRS-P in patients with 
ADHD.
A strength of the present correlational analyses is the 
focus on changes during treatment rather than baseline 
impairments. However, the inclusion criteria may also have 
allowed greater scope for change in the primary efficacy 
outcome measure than in secondary efficacy outcome mea-
sures. The treatment groups were not pooled for these cor-
relative analyses. This approach might have increased 
statistical power, but would not have allowed possible treat-
ment-specific effects to be discerned. Results for the 
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placebo groups in the present analyses are not reported 
because correlation coefficients were low, presumably due 
to the smaller changes in scores on outcome measures than 
those observed in the active treatment groups. Although 
placebo-adjusted effect sizes of ATX in SPD503-316 were 
similar to those reported in other studies (Cheng et al., 
2007; Escobar et al., 2010), the magnitude of changes and 
the number of participants may also not have been large 
enough to enable relationships between outcomes to be 
assessed adequately. We did not test statistically whether 
values of Pearson’s r differed from one another, so conclu-
sions about differences in the strength of relationships 
between outcomes and treatment groups remain suggestive. 
Finally, the analyses were not corrected for multiplicity, so 
p values should be interpreted as descriptive, not 
inferential.
The present study suggests potential areas for future 
research. In particular, a study investigating the relationship 
between parent-rated symptom outcomes with parent-rated 
functional impairment and HRQoL outcomes may provide 
further insight into the relationships between these con-
structs in children with ADHD. Similarly, an investigation 
of the relationship between patient-rated symptoms and 
functional impairment or HRQoL may provide further 
insight into the relationships between these constructs in 
adolescents or adults with ADHD. Finally, the question of 
whether particular medications may have similar efficacy in 
providing symptomatic relief but subtly different effects in 
particular domains of functional impairment or HRQoL 
remains to be investigated.
In conclusion, the findings of these post hoc analyses 
suggest that relief of ADHD symptoms during short-term 
treatment with ADHD medication is generally associated 
with reduced functional impairments and improved 
HRQoL. This should provide further incentive for physi-
cians to aim for optimal control of ADHD symptoms with 
a well-tolerated medication. At the same time, these find-
ings also suggest that factors other than reductions in 
ADHD symptom scores also influence improvements in 
functioning and HRQoL. This should encourage physi-
cians to explore potential benefits of therapeutic interven-
tions that fall outside of those captured by conventional 
ADHD symptom scales. Finally, the findings also support 
the inclusion of functional impairment and HRQoL mea-
sures as outcomes of clinical trials in patients with ADHD 
and highlight the need for further development and 
improved understanding of the available instruments, on 
the grounds that they do appear to sample different, but 
partially intersecting, aspects of the treatment response, 
beyond relief of ADHD symptoms.
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